研究揭示了 PD-L1 表达与疾病阶段、病理亚型、年龄、性别和吸烟史等因素的显著关系,早期患者免疫治疗耐药基因的发生率较低,尤其是高 PD-L1 表达的患者。这体现了 NSCLC 在不同阶段和 PD-L1 表达水平下的高度异质性。 早期患者高 PD-L1 表达的病例较少,可能是因为早期肿瘤尚未形成免疫逃逸机制。PD-L1 表达在疾...
L1 antibodies, we show that the presence of mature TLSs was associated with improved objective response rates, progression-free survival and overall survival, independent of PD-L1 expression status and CD8+T cell density. These results pave the way for using TLS detection to select patients who ...
4, James T Handa3, Evan J Lipson4 and Janis M Taube1,2,4 PD-L1 expression in the tumor immune microenvironment is recognized as both a prognostic and predictive biomarker in patients with cutaneous melanoma, a finding closely related to its adaptive (IFN-γ-mediated) mechanism of expression...
PD-1/PD-L1–targeted immunotherapy has emerged as a promising therapeutic strategy for pulmonary adenocarcinoma (pADC). Epithelial-to-mesenchymal transition (EMT) is involved in the progression and immune evasion of cancers. Therefore, we investigated the association between PD-L1 expression and EMT ...
Notably, the different immunosuppression capacities of WJ-MSCs were positively correlated with PD-L1 expression. WJ-MSCs with high expression of PD-L1 were therapeutically superior to WJ-MSCs with low PD-L1 expression in treating autoimmune hepatitis. Conclusion PD-L1 expression levels of WJ-MSCs ...
There was a broad range of PD-1 and PD-L1 expression in our cohort with expression of PD-L1 noted exclusively on either tumor or non-tumor cells or on both within the tissue. However, our combination of IHC staining with genomic profiles of flow-sorted tumor populations in our cohort of...
lung, breast and renal cell carcinomas (4-6).PD-L1 expression in cancer cells is associated with tumor-infiltrating lymphocytes, which mediate PD-L1 expression through the release of interferon gamma (7).Other studies have implicated PD-L1 expression in viral infection-related cancers (8,9). ...
PD-L1, the major PD-1 ligand, is expressed on various tumors and is being investigated as a possible predictive marker for anti-PD-1 therapy. Few studies have determined PD-L1 expression across tumor types using a consistent process. We evaluated PD-L1 expression across human tumor samples ...
The programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) have shown positive efficacy in several solid cancers due to their targeted antitumour effects. However, the frequency and clinical implication value in prostate cancer still remain unclear. Methods The PD-1/PD-L1 expression was ...
We examined the expression of Programmed Death Ligand 1 (PD-L1) and defined the tumor immune microenvironment to assess the prognostic utility in osteosarcoma. PD-L1 expression in osteosarcoma was examined in two patient cohorts using immunohistochemistry (IHC) (n = 48, n = 59) and ...